Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRE NASDAQ:HCM NASDAQ:RARE NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$6.19+8.8%$7.01$5.44▼$9.42$600.62M1.991,614 shs133,446 shsHCMHUTCHMED$11.17-1.2%$13.61$11.00▼$19.50$1.95B0.2639,462 shs97,732 shsRAREUltragenyx Pharmaceutical$23.31+4.0%$23.56$18.29▼$42.37$2.30B0.372.13 million shs1.41 million shsRXRXRecursion Pharmaceuticals$3.80+9.5%$3.29$2.77▼$7.18$2.01B1.0417.31 million shs38.57 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics+2.34%-3.89%-27.05%-27.33%-30.78%HCMHUTCHMED-1.82%-3.50%-14.96%-18.34%-23.06%RAREUltragenyx Pharmaceutical+2.89%-4.19%-9.53%+4.43%-38.43%RXRXRecursion Pharmaceuticals-3.88%+9.46%+2.36%-1.98%-20.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$6.19+8.8%$7.01$5.44▼$9.42$600.62M1.991,614 shs133,446 shsHCMHUTCHMED$11.17-1.2%$13.61$11.00▼$19.50$1.95B0.2639,462 shs97,732 shsRAREUltragenyx Pharmaceutical$23.31+4.0%$23.56$18.29▼$42.37$2.30B0.372.13 million shs1.41 million shsRXRXRecursion Pharmaceuticals$3.80+9.5%$3.29$2.77▼$7.18$2.01B1.0417.31 million shs38.57 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics+2.34%-3.89%-27.05%-27.33%-30.78%HCMHUTCHMED-1.82%-3.50%-14.96%-18.34%-23.06%RAREUltragenyx Pharmaceutical+2.89%-4.19%-9.53%+4.43%-38.43%RXRXRecursion Pharmaceuticals-3.88%+9.46%+2.36%-1.98%-20.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 2.00Hold$17.00174.64% UpsideHCMHUTCHMED 2.40Hold$16.8050.40% UpsideRAREUltragenyx Pharmaceutical 2.82Moderate Buy$59.56155.52% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10113.16% UpsideCurrent Analyst Ratings BreakdownLatest GYRE, RARE, RXRX, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/21/2026RAREUltragenyx Pharmaceutical Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$84.00 ➝ $96.005/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/8/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026RAREUltragenyx Pharmaceutical GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.005/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/6/2026RAREUltragenyx Pharmaceutical Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $47.005/6/2026RAREUltragenyx Pharmaceutical WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$27.00 ➝ $26.005/1/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$116.59M5.15$0.25 per share25.02$1.48 per share4.18HCMHUTCHMED$548.51M3.55$2.62 per share4.27$7.17 per share1.56RAREUltragenyx Pharmaceutical$673M3.41N/AN/A($0.83) per share-28.08RXRXRecursion Pharmaceuticals$74.68M26.96N/AN/A$2.14 per share1.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)HCMHUTCHMED$456.91MN/AN/A19.26N/AN/AN/AN/A6/4/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest GYRE, RARE, RXRX, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2026N/AHCMHUTCHMED-$0.3581N/AN/AN/A$80.92 millionN/A5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 million3/6/2026H2 2025HCMHUTCHMED$2.50$0.0060-$2.4940N/A$290.50 million$135.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A4.644.06HCMHUTCHMED0.054.964.83RAREUltragenyx PharmaceuticalN/A2.021.85RXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%HCMHUTCHMED8.82%RAREUltragenyx Pharmaceutical97.67%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics9.50%HCMHUTCHMED3.60%RAREUltragenyx Pharmaceutical5.20%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4097.03 million87.81 millionNo DataHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableGYRE, RARE, RXRX, and HCM HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 12.5% Higher - Here's What Happened4 hours ago | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 ResultsJune 4 at 1:17 PM | finance.yahoo.comRecursion’s AI Drug Pipeline Progress Tests Investor Patience And ValuationJune 4 at 8:16 AM | finance.yahoo.comThree AI Healthcare Stocks Chart Distinct Growth TrajectoriesJune 2 at 11:35 PM | nai500.comNRecursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?June 2 at 6:34 PM | fool.comRecursion to Participate in Upcoming Investor ConferencesJune 2 at 8:32 AM | finance.yahoo.comRecursion to Participate in Upcoming Investor ConferencesJune 2 at 8:00 AM | globenewswire.comLingotto Investment Management LLP Buys 1,255,980 Shares of Recursion Pharmaceuticals, Inc. $RXRXJune 2 at 6:55 AM | marketbeat.comRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesMay 29, 2026 | finance.yahoo.comRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesMay 29, 2026 | globenewswire.comVerge, following trial failure, rebrands its AI drug discovery ambitionsMay 27, 2026 | biopharmadive.comBRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.9% Higher - Here's WhyMay 27, 2026 | marketbeat.comRecursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)May 27, 2026 | marketbeat.comRecursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?May 25, 2026 | fool.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | finance.yahoo.comA Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth ProspectsMay 23, 2026 | finance.yahoo.comMorgan Stanley Raises its Price Target on Recursion (RXRX)May 22, 2026 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low - Here's What HappenedMay 19, 2026 | marketbeat.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | finance.yahoo.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026MP Materials Is Quietly Building a Rare Earth PowerhouseBy Leo Miller | May 12, 20263 Ways to Target the Resources Powering AI and Data CentersBy Nathan Reiff | May 10, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsBy Leo Miller | May 20, 2026GYRE, RARE, RXRX, and HCM Company DescriptionsGyre Therapeutics NASDAQ:GYRE$6.19 +0.50 (+8.79%) Closing price 04:00 PM EasternExtended Trading$6.19 0.00 (0.00%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.HUTCHMED NASDAQ:HCM$11.17 -0.14 (-1.24%) Closing price 04:00 PM EasternExtended Trading$11.17 +0.00 (+0.04%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Ultragenyx Pharmaceutical NASDAQ:RARE$23.31 +0.90 (+4.02%) Closing price 04:00 PM EasternExtended Trading$23.30 -0.01 (-0.06%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Recursion Pharmaceuticals NASDAQ:RXRX$3.80 +0.33 (+9.51%) Closing price 04:00 PM EasternExtended Trading$3.78 -0.01 (-0.39%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
